Literature DB >> 21663937

PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck.

Justin A Bishop1, Rajni Sharma, William H Westra.   

Abstract

Anaplastic thyroid carcinoma can be difficult to diagnose because it does not show thyroid differentiation morphologically or immunohistochemically. Depending on the histologic variant, anaplastic thyroid carcinoma may be confused with sarcoma or squamous cell carcinoma of the head and neck. PAX8 is a transcription factor expressed in normal and neoplastic thyroid follicular epithelium and only a few other tissues. This restricted expression suggests that PAX8 staining could be useful when dealing with spindled or squamoid tumors of the neck. The purposes of this study were to determine the frequency of PAX8 staining in anaplastic thyroid carcinoma and to evaluate PAX8 immunohistochemistry as a means of distinguishing its squamoid variant from head and neck squamous cell carcinoma. PAX8 immunohistochemical staining was performed on 34 anaplastic thyroid carcinomas and 118 head and neck squamous cell carcinomas. PAX8 staining was present in 26 (76%) anaplastic thyroid carcinomas including 16 (100%) of 16 squamoid variants, 7 (58%) of 12 giant cell/pleomorphic variants, and 3 (50%) of 6 spindled variants. All head and neck squamous cell carcinomas were negative for PAX8. PAX8 expression is often retained in anaplastic thyroid carcinomas including the squamoid variant, but it is not expressed in head and neck squamous cancers. PAX8 staining is an excellent marker for carcinomas of follicular epithelial origin, including those carcinomas that are undifferentiated in other respects. The tissue specificity of PAX8 expression may be useful in resolving the differential diagnosis of anaplastic thyroid carcinoma such as the distinction between its squamoid variant and squamous cell carcinoma of the head and neck.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21663937     DOI: 10.1016/j.humpath.2011.02.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  35 in total

1.  Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.

Authors:  Manoj Garg; Ryoko Okamoto; Yasunobu Nagata; Deepika Kanojia; Subhashree Venkatesan; Anand M T; Glenn D Braunstein; Jonathan W Said; Ngan B Doan; Quoc Ho; Tadayuki Akagi; Sigal Gery; Li-Zhen Liu; Kar Tong Tan; Wee Joo Chng; Henry Yang; Seishi Ogawa; H Phillip Koeffler
Journal:  J Clin Endocrinol Metab       Date:  2014-11-03       Impact factor: 5.958

Review 2.  Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma.

Authors:  Tyler Janovitz; Justine A Barletta
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

3.  Tumor cell anaplasia and multinucleation are predictors of disease recurrence in oropharyngeal squamous cell carcinoma, including among just the human papillomavirus-related cancers.

Authors:  James S Lewis; Juliette B Scantlebury; Jingqin Luo; Wade L Thorstad
Journal:  Am J Surg Pathol       Date:  2012-07       Impact factor: 6.394

4.  Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion gene.

Authors:  Thais Basili; Higinio Dopeso; Sarah H Kim; Lorenzo Ferrando; Fresia Pareja; Arnaud Da Cruz Paula; Edaise M da Silva; Anthe Stylianou; Ana Maroldi; Caterina Marchiò; Brian P Rubin; Mauro Papotti; Britta Weigelt; Carlos Gil Moreira Ferreira; José Roberto Lapa E Silva; Jorge S Reis-Filho
Journal:  Int J Cancer       Date:  2020-05-21       Impact factor: 7.396

5.  Diagnosis and Treatment of Metastases to the Thyroid Gland: a Meta-Analysis.

Authors:  Patrizia Straccia; Claudia Mosseri; Chiara Brunelli; Esther Diana Rossi; Celestino Pio Lombardi; Alfredo Pontecorvi; Guido Fadda
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

6.  Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas.

Authors:  Hasan Gucer; Sultan Caliskan; Mehmet Kefeli; Ozgur Mete
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

Review 7.  Anaplastic Transformation of Papillary Thyroid Carcinoma Only Seen in Pleural Metastasis: A Case Report with Review of the Literature.

Authors:  Hyunsung Kim; Yong Wook Park; Young-Ha Oh; Jongmin Sim; Jae Y Ro; Ju Yeon Pyo
Journal:  Head Neck Pathol       Date:  2016-08-22

Review 8.  Rhabdomyoblastic Differentiation in Head and Neck Malignancies Other Than Rhabdomyosarcoma.

Authors:  Justin A Bishop; Lester D R Thompson; Antonio Cardesa; Leon Barnes; James S Lewis; Asterios Triantafyllou; Henrik Hellquist; Goran Stenman; Jennifer L Hunt; Michelle D Williams; Pieter J Slootweg; Kenneth O Devaney; Douglas R Gnepp; Bruce M Wenig; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck Pathol       Date:  2015-03-11

Review 9.  Immunohistochemical Biomarkers of Mesenchymal Neoplasms in Endocrine Organs: Diagnostic Pitfalls and Recent Discoveries.

Authors:  Yin P Hung; Jason L Hornick
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 10.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.